An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
NCT00292084
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C, Chronic
Interventions
DRUG:
Celgosivir
Sponsor
BioWest Therapeutics Inc